VERIFIEDEconomic Times News·3 Aug 2026positive

MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline

AI Summary

·Sun Pharma's June quarter results met analyst expectations.
·The company is expanding its specialty and innovative medicines portfolio significantly.
·Analysts anticipate substantial growth from ventures like semaglutide launches and the Organon acquisition.